Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 10
Submit an article Journal homepage
1,585
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)

Meagan A. Jacobya Washington University School of Medicine, St. Louis, MO, USACorrespondence[email protected]
View further author information
,
Laura Finnb Ochsner Health, New Orleans, LA, USAView further author information
,
Ashkan Emadic University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USAView further author information
,
Nakhle S. Sabad Tulane University School of Medicine, New Orleans, LA, USAORCID Iconhttps://orcid.org/0000-0003-3206-2575View further author information
ORCID Icon,
Bayard L. Powelle Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USAView further author information
,
Karen Seiterf New York Medical College, Valhalla, NY, USAView further author information
,
Rosella Garciag Jazz Pharmaceuticals, Palo Alto, CA, USAView further author information
,
Stefan Faderlg Jazz Pharmaceuticals, Palo Alto, CA, USAView further author information
&
Heather J. Maleh University of Kansas Medical Center, Kansas City, KS, USAView further author information
 show all
Pages 2539-2542 | Received 08 Apr 2021, Accepted 12 Apr 2021, Published online: 11 May 2021

References

  • DOXIL® (doxorubicin hydrochloride liposomal injection), for intravenous use [prescribing information]. Deerfield (IL): Baxter Healthcare Corporation; 2019.
  • AmBisome® (amphotericin B) liposome for injection [prescribing information]. Northbrook (IL): Astellas Pharma US, Inc.; 2020.
  • Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854–1863.
  • Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34(9):1214–1223.
  • Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129–139.
  • Kim HP, Gerhard B, Harasym TO, et al. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011;39(7):741–750.
  • European Medicines Agency: Vyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusion [Internet; accessed December 9, 2020]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal.
  • VYXEOS® (daunorubicin and cytarabine) liposome for injection, for intravenous use [prescribing information]. Palo Alto (CA): Jazz Pharmaceuticals, Inc.; 2021.
  • Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692.
  • Lancet JE, Uy GL, Newell LF, et al. Five-year final results of a phase III study of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. J Clin Oncol. 2020;38(15_suppl): Abstract 7510.
  • Szebeni J, Simberg D, González-Fernández A, et al. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol. 2018;13(12):1100–1108.
  • Mayer LD, Tardi P, Louie AC. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine. 2019;14:3819–3830.
  • Roboz GJ, Larson ML, Rubenstein SE, et al. Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia. Leuk Lymphoma. 2020;61(5):1188–1194.
  • Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239–3246.
  • Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015;121(2):234–242.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.